Abstract
It seems hard to believe that in the early 1990s MTX use by a respected group of UK rheumatologists in nine hospitals only represented 3% of all DMARDs used for a cohort of patients presenting with early RA [1]. It is now the most widely used DMARD, not only for RA, but is effective for both psoriasis and PsA [2, 3]. It has also become our principal anchor drug in combination therapy, including the anti-TNF agents, where recent data suggests that their combination is our best treatment option yet in RA [4]. As a cheap, effective and usually well-tolerated drug it is not surprising that prescribing it worldwide has continued to rise exponentially and that the patients may be on it commonly for >5 yrs.

This publication has 30 references indexed in Scilit: